報價延遲最少15分鐘:2026/04/25 04:13 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
41.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
23.03/20.80
|
|
企業價值
289.79B
|
| 資產負債 |
|
每股賬面淨值
6.90
|
| 現金流量 |
|
現金流量率
0.11
|
| 損益表 |
|
收益
309.06B
|
|
每股收益
6.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
